GLP-1 Non-Responders: Why Genetics and Receptor Variants Limit Blood Sugar Drops in Type 2 Diabetes

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the treatment of metabolic disease. These therapies stimulate insulin secretion, delay gastric emptying, and suppress appetite. Yet in everyday medical practice, clinicians notice a striking divergence in patient outcomes. While some individuals experience dramatic improvements in blood sugar and body weight, others see very little change. Think of the medication as a precision-cut key designed to turn a specific metabolic lock. If inherited DNA variations alter the internal tumblers of that lock, the key cannot turn, leaving the cellular machinery unresponsive.

A large-scale investigation reveals why this divide occurs. Analyzing electronic health records and genetic data from 5,784 adults with type 2 diabetes in the All of Us research program, scientists identified specific genetic markers that explain this variable response. The findings, reported in a MedRxiv preprint study, highlight how common receptor variations and overall genetic risk burden dictate whether an individual responds robustly to GLP-1 therapies.

The GLP-1 Paradox: Unequal Responses to Incretin Therapy

Clinical trials have repeatedly shown substantial reductions in glycated hemoglobin (HbA1c, a standard measure of average blood sugar over three months) among patients taking incretin mimetics. A comprehensive systematic review published in Medicine confirms that GLP-1-based pharmacotherapies produce reliable weight loss and glycemic benefits across diverse populations. However, real-world data paints a more nuanced picture.

In the All of Us cohort of 5,784 adults initiating GLP-1RA therapy, patients naturally split into two distinct groups. Good responders, defined as individuals achieving an HbA1c reduction of at least 2.5 percentage points after three months, saw their average blood glucose marker drop from 9.2% down to 6.3%. This represents a substantial 2.9 percentage point absolute drop. By contrast, poor responders (those achieving less than a 0.5 percentage point drop) experienced an average shift from 8.4% to just 8.1%, representing a minor 0.3 percentage point reduction.

This gap extended far beyond glycemic control alone. Good responders experienced larger decreases in body mass index, systolic and diastolic blood pressure, triglycerides, and liver enzymes. Poor responders were slightly older on average (58.6 years versus 55.2 years) and exhibited significantly blunted cardiometabolic improvements across the board. Understanding these divergent paths is critical, especially since unmanaged glucose levels can compound over time. As explored in our analysis of how type 2 diabetes accelerates cellular aging, sustained metabolic dysregulation places persistent stress on vascular and cellular systems.

Decoding the Receptor: GLP1R Variants and Polygenic Architecture

To uncover the biological roots of treatment failure, investigators looked directly at the GLP1R gene, which carries the blueprints for building the GLP-1 receptor on pancreatic beta cells and other tissues. They also calculated each participant's polygenic risk score, a composite metric that sums the cumulative burden of thousands of small genetic variants linked to type 2 diabetes.

The genetic analysis revealed three decisive findings:

• Higher Overall Polygenic Risk Load: Poor responders carried a significantly higher type 2 diabetes polygenic risk score than good responders (0.38 versus 0.21 after multivariable adjustment), reflecting a heavier underlying genetic predisposition toward beta-cell dysfunction.
• Increased Coding Variant Burden: Individuals who failed to respond carried a higher prevalence of GLP1R coding variants (10.1% versus 8.0%) and a higher overall GLP1R variant carrier burden (22.8% versus 19.2%).
• Specific Inhibitory Variants: Detailed variant mapping identified two specific genetic alterations, known as rs2268650 and rs2003132, that were significantly enriched in poor responders. Carriers of these specific variants exhibited negative post-treatment HbA1c trajectories, indicating that the altered receptor structure could not efficiently translate drug binding into intracellular signaling.

These data demonstrate that therapy resistance is frequently hardwired at the genomic level. When a receptor's structural conformation is altered by single nucleotide polymorphisms, synthetic peptide agonists cannot trigger the downstream release of cyclic adenosine monophosphate (cAMP, a vital intracellular messenger molecule that signals the cell to release insulin). Understanding such genetic variation helps clarify why metabolic responses differ so widely across individuals, a concept also seen in evolutionary genomics and insulin resistance.

Beyond Single Agonism: Next-Generation Multi-Target Metabolic Therapies

Because single-receptor mutations can hinder treatment success, pharmaceutical research is shifting toward multi-target molecules. When a patient carries a structural variation in the GLP-1 receptor, relying solely on GLP-1 agonism creates a therapeutic bottleneck. Activating alternative metabolic pathways simultaneously can help circumvent this obstacle.

Recent work published in Cardiovascular Diabetology highlights the emergence of multi-agonist therapies that combine incretin receptor targeting with nuclear receptor modulation. Researchers developed a single-molecule conjugate known as GLP-1-GIP-lanifibranor. This agent binds to both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors while delivering lanifibranor directly into target cells to activate peroxisome proliferator-activated receptors (PPARs, nuclear proteins that govern lipid metabolism and insulin sensitivity).

In preclinical models of obesity and diabetes, this dual incretin and pan-PPAR approach produced greater reductions in body weight, food intake, and blood sugar than single-target GLP-1 therapy or co-agonism alone. Crucially, the activation of PPAR-delta signaling drove improvements in glycemic control independently of weight loss. By engaging multiple cellular receptors at the same time, next-generation therapies may offer a viable workaround for individuals who carry poor-responder GLP1R variants.

Study Limitations and Scientific Context

While these genomic insights provide a clearer understanding of treatment variability, several limitations must be considered. First, the primary genetic association study is currently hosted as a preprint on MedRxiv. It provides valuable observational data from 5,784 individuals, but it has not yet completed formal peer review. Observational electronic health record data can also contain unmeasured confounding factors, such as differences in medication adherence, dosage titration schedules, or concurrent dietary patterns.

Additionally, while the study identified an enrichment of rs2268650 and rs2003132 variants among poor responders, genetic screening for these markers is not yet routinely standardized in commercial clinical laboratories. Preclinical data for multi-target conjugates like GLP-1-GIP-lanifibranor are currently limited to animal models and require human clinical trial validation before entering clinical practice.

Precision Incretin Medicine: Personalizing Metabolic Care

Personalizing metabolic treatment requires tracking objective biomarker responses early in the course of therapy. Because GLP-1 resistance often becomes apparent within the first 90 days, monitoring metabolic changes allows clinicians to adjust treatment strategies rather than maintaining an ineffective regimen.

Clinical Action Protocol

• Baseline Biomarker Profiling: Prior to initiating incretin therapy, obtain a comprehensive metabolic baseline. This should include HbA1c, fasting plasma glucose, fasting insulin, high-sensitivity C-reactive protein (hs-CRP), and a complete lipid subfraction panel.
• 90-Day Trajectory Assessment: Measure HbA1c and fasting glucose at the 12-week mark. If HbA1c reduction is less than 0.5 percentage points despite adequate dosing and compliance, discuss non-responder genetics with your physician.
• Therapeutic Pivot: For poor responders, clinical guidelines support evaluating alternative or dual-incretin therapies (such as combined GLP-1/GIP receptor agonists) or adding complementary insulin-sensitizing agents to bypass single-receptor limitations.

Recognizing that receptor genetics dictate clinical outcomes helps shift diabetes management away from trial-and-error prescribing and toward targeted, personalized therapy.